A Rare Case of Midostaurin-Associated Sweet’s Syndrome

Yasin, Hesham; Laytem, Tessa; Sutamtewagul, Grerk; Ayyappan, Sabarish

doi:10.1155/2022/1099005

Cited by 3 publications

(1 citation statement)

References 25 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the pivotal trial that led to approval of midostaurin, there were no reported cases of DS occurring in patients using midostaurin and, to our knowledge, there have been no cases of DS attributed to midostaurin reported in the literature [82]. However, there have been case reports of AFND/Sweet's Syndrome associated with the use of midostaurin in the literature that have resolved with corticosteroid treatment [92,93]. AFND/Sweet's syndrome has been described with other FLT3 inhibitors previously as a manifestation of terminal differentiation of FLT3-mutated blasts [94][95][96].…”

Section: Flt3 Inhibitorsmentioning

confidence: 99%

Differentiation Syndrome in Acute Leukemia: APL and Beyond

Woods,

Norsworthy

2023

Cancers

View full text Add to dashboard Cite

Differentiation syndrome (DS) is a frequent and potentially life-threatening clinical syndrome first recognized with the advent of targeted therapeutics for acute promyelocytic leukemia (APL). DS was subsequently observed more broadly with targeted therapeutics for acute myeloid leukemia (AML). DS is typically characterized by fever, dyspnea, hypotension, weight gain, pleural or pericardial effusions, and acute renal failure. The incidence in patients with APL ranges from 2 to 37%, with the wide variation likely attributed to different diagnostic criteria, use of prophylactic treatment, and different treatment regimens. Treatment with corticosteroids +/- cytoreductive therapy should commence as soon as DS is suspected to reduce DS-related morbidity and mortality. The targeted anti-leukemic therapy should be discontinued in patients with severe DS. Here, we discuss the pathogenesis of DS, clinical presentations, diagnostic criteria, management strategies, and implementation of prospective tracking on clinical trials.

show abstract